Novavax’s COVID-19 Vaccine Boost From First Phase I Data
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.